BRC News

239 people have so far joined the registry of healthy volunteers willing to be contacted about taking part in health research.

The trial aims to improve independence for people who are paralysed.

Premature birth can pose risks to a newborn baby, as many organs are still developing in the final weeks of pregnancy.

The global study involves patients with advanced lung cancer.

It follows landmark findings from a clinical trial supported by the BRC.

The team say nutritional guidance should always be given alongside treatment, and that further research is needed into what this guidance should be.

An end of year newsletter from the NIHR UCLH Clinical Research Facility is out now.

The FORTRESS study is looking at a novel treatment for locally advanced rectal cancer.

A UK biotech company based on UCL research has raised $33 million from investors to begin early-phase trials of a potential new treatment for people with severe epilepsy.

A new spinout company will advance digital transformation at NHS organisations and international healthcare providers to improve patient care, patient safety and population health and research.

The NIHR has committed £16 million to the trial.

The research from a BRC supported team is published in the New England Journal of Medicine.

The BRC-supported research team will run a clinical trial of LungVax over the next four years.

The development of the breakthrough immunotherapy has had long-standing support from the BRC at UCLH.

In the current financial year, UCLH has recruited the first participant in the world to three clinical trials.